Levetiracetam (All indications)

Maternal consequences (as a whole)

R analysis
id Study   Lib. in paper Exposition period    Study type 
 Control type 
 
Tags OR 95%CI x1/n1 x0/n0 no cases no exposed ROB Ref.
S12704
R47940		 Alsfouk (Levetiracetam), 2022 Maternal complication (bleeding during pregnancy, gestational hypertension, eclampsia, preeclampsia, gestational diabetes, cervical cerclage, placenta abruption, prolonged labor, pre-mature rupture of membranes, seizure on day of delivery or during delivery, and post-partum hemorrhage) during pregnancy (anytime or not specified) retrospective cohort exposed to other treatment, sick Adjustment: No 1.33 [0.28;6.39] C 6/24   3/15 9 24
ref
Total 1 studies 1.33 [0.28;6.39] 9 24
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives

Forest plot

StudyTE95% CIn casesn exposedweightROBABCDEF Alsfouk (Levetiracetam), 2022Alsfouk, 2022 1 1.33[0.28; 6.39]9240%ROB confusion: criticalROB selection: criticalROB classification: moderateROB missing: unclearROB mesure: moderateROB reporting: moderate0.55.01.0ROB: A: confusion, B: selection, C: classification, D: missing, E: measurement, F: reportinglow,moderate,serious,critical,unclear,

1: Levetiracetam;

Sensitivity analysis

SubsetTE95% CIn casesn exposedkI2 Type of studies cohort studiescohort studies 1.33[0.28; 6.39]924 -NAAlsfouk (Levetiracetam), 2022 1 case control studiescase control studies 0 Type of controls exposed to other treatment, sickexposed to other treatment, sick 1.33[0.28; 6.39]924 -NAAlsfouk (Levetiracetam), 2022 1 Tags Adjustment   - No  - No 1.33[0.28; 6.39]924 -NAAlsfouk (Levetiracetam), 2022 1 All studiesAll studies 1.33[0.28; 6.39]924 -NAAlsfouk (Levetiracetam), 2022 10.55.01.0

Publication bias and p-hacking diagnosis

funnel plot

Funnel plot not drawn. Less than 3 points.

Asymetry test p-value = NaN (by Egger's regression)

not enought points

p values plot

Funnel plot not drawn. Less than 3 points.

Sub-groups analysis using all included studies

excluded

Sub-groupsTE95% CIn casesn exposedkI2ROB type of controls exposed to other treatment, sick controlsexposed to other treatment, sick controls 1.33[0.28; 6.39]924 -NAAlsfouk (Levetiracetam), 2022 10.510.01.0